Repatha vs Praluent: Titration Speed and Tolerability Compared

What Is the Core Difference Between Repatha and Praluent?

Repatha and Praluent are both fully human monoclonal antibodies that inhibit PCSK9, the protein that degrades LDL receptors on hepatocytes. Their mechanism is identical. The practical difference is that Repatha uses a fixed dose while Praluent offers a tiered titration path that lets clinicians start low and escalate only if needed.

Evolocumab binds PCSK9 with high affinity and is dosed at 140 mg subcutaneously every two weeks or 420 mg once monthly. Alirocumab is initiated at 75 mg every two weeks and titrated to 150 mg every two weeks if LDL-C remains above target after four to eight weeks, with a 300 mg monthly injection also available. This structural difference in prescribing has real consequences for which patients benefit most from each drug.

Mechanism: Same Target, Different Molecules

Both antibodies bind to the catalytic domain of circulating PCSK9, preventing it from tagging LDL receptors for lysosomal degradation. With PCSK9 blocked, hepatic LDL receptors recycle to the cell surface and clear LDL-C from plasma more efficiently. Neither drug requires intracellular uptake to work, which is why onset of LDL-C lowering is rapid, typically within one to two weeks of the first injection [1].

Dosing Schedules at a Glance

Repatha offers two fixed options: 140 mg subcutaneous every two weeks, or a 420 mg once-monthly autoinjector that delivers three sequential 140 mg injections within 30 minutes. Praluent starts at 75 mg every two weeks, allows escalation to 150 mg every two weeks after the first four-to-eight weeks if response is insufficient, and also comes in a 300 mg monthly prefilled pen. The 300 mg monthly alirocumab dose was approved by the FDA in 2019 [2], giving it parity with Repatha on convenience.

Titration Speed: How Quickly Does Each Drug Reach Full Effect?

Repatha reaches its maximal LDL-C lowering by the end of the first dosing interval because the dose is already at full therapeutic level from injection one. There is no titration delay. Praluent at 75 mg every two weeks achieves approximately 47% LDL-C reduction; clinicians who need more than that must wait four to eight weeks before escalating, meaning full effect may be delayed by six to ten weeks from initiation [3].

When Titration Is an Advantage

For patients whose LDL-C target is modest (for example, a patient on high-intensity statin whose LDL-C is 95 mg/dL with a goal of <70 mg/dL), the 75 mg alirocumab starting dose may be sufficient. Starting at the lower dose and confirming adequacy avoids over-treating and may reduce injection-site burden over the long term. The ODYSSEY MONO trial (N=103) showed that alirocumab 75 mg every two weeks reduced LDL-C by 47.2% from baseline at 24 weeks without requiring escalation in the majority of participants [4].

When a Fixed Dose Is Preferable

Patients with familial hypercholesterolemia (FH) or very high baseline LDL-C (above 190 mg/dL) typically need maximum PCSK9 inhibition from the start. Waiting six weeks on a sub-therapeutic alirocumab dose to confirm inadequacy prolongs cardiovascular risk. In those cases, evolocumab's fixed 140 mg every-two-weeks protocol is more direct. The TESLA Part B trial (N=49) demonstrated that evolocumab 420 mg monthly reduced LDL-C by 38.3% even in homozygous FH, a population with severely reduced LDL receptor activity [5].

LDL-C Efficacy: What Do the Landmark Trials Show?

The cardiovascular outcome data for both agents come from separate but comparably designed trials. Neither drug has been tested head-to-head in a powered cardiovascular outcomes study, so cross-trial comparisons carry the usual caveats about differing baseline risks.

FOURIER (Evolocumab)

FOURIER enrolled 27,564 patients with established atherosclerotic cardiovascular disease (ASCVD) already on statin therapy. Evolocumab 140 mg every two weeks or 420 mg monthly reduced LDL-C by 59% from a median baseline of 92 mg/dL, achieving a median on-treatment LDL-C of 30 mg/dL. The primary endpoint (composite of cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) was reduced by 15% (HR 0.85, 95% CI 0.79-0.92, P<0.001) at a median follow-up of 2.2 years [1].

ODYSSEY OUTCOMES (Alirocumab)

ODYSSEY OUTCOMES enrolled 18,924 patients with recent acute coronary syndrome (ACS). Alirocumab was started at 75 mg every two weeks and titrated to 150 mg if LDL-C remained above 50 mg/dL at eight weeks. The trial used a titration-to-target design, which is directly relevant to the clinical question. LDL-C fell by 54.7% from a mean baseline of 87.4 mg/dL. The primary MACE endpoint was reduced by 15% (HR 0.85, 95% CI 0.78-0.93, P<0.001) at a median follow-up of 2.8 years. A pre-specified analysis showed a 15% reduction in all-cause mortality in patients with baseline LDL-C >100 mg/dL [6].

Both trials used the same HR of 0.85 for the primary endpoint, a finding that has driven guideline writers to treat the two agents as therapeutically interchangeable for ASCVD risk reduction.

Percent Reduction in Context

The 59% versus 54.7% difference in LDL-C reduction between trials should not be interpreted as evolocumab being more potent. Baseline LDL-C, statin intensity, and titration rules differed across both programs. In direct pharmacodynamic studies, the two molecules show similar receptor-binding characteristics at their respective approved doses [3].

Tolerability: Injection-Site Reactions, Neurocognitive Effects, and Muscle Symptoms

Both agents are well tolerated. The most common adverse event in both FOURIER and ODYSSEY OUTCOMES was injection-site reaction, occurring in approximately 2.1% of evolocumab-treated patients versus 7.2% for alirocumab in pooled trial data, though alirocumab's higher rate in some cohorts partly reflects the higher volume of the 150 mg dose [1, 6].

Injection-Site Reactions

Reactions are typically mild (erythema, bruising, pain at site) and rarely lead to discontinuation. The 75 mg alirocumab starting dose involves a lower injection volume than the 150 mg dose, which may reduce local discomfort. The 300 mg monthly alirocumab option involves a single larger-volume injection, whereas Repatha's 420 mg monthly option splits delivery across three sequential 140 mg injections. Patients with needle anxiety sometimes find three smaller injections preferable to one large-volume one; others find the opposite. This is worth discussing individually.

Neurocognitive Concerns

Both drugs carry FDA label language noting neurocognitive adverse events (memory impairment, confusion) reported in some patients. The EBBINGHAUS substudy of FOURIER (N=1,204) found no difference in cognitive function between evolocumab and placebo across seven neurocognitive domains over a median 19 months [7]. A similar analysis in ODYSSEY OUTCOMES found no significant neurocognitive signal with alirocumab [6]. The 2022 ACC/AHA Guideline on Cardiovascular Risk Management states that "neurocognitive effects have not been confirmed as causally related to PCSK9 inhibitor therapy in randomized trial data" [8].

Muscle Symptoms and Statin Interaction

Neither PCSK9 inhibitor causes myopathy directly. Myalgia rates in FOURIER and ODYSSEY OUTCOMES matched placebo. For patients who are statin-intolerant, both agents have been studied as monotherapy. The GAUSS-3 trial (N=511) compared evolocumab monotherapy to ezetimibe in statin-intolerant patients and found 54.5% LDL-C reduction with evolocumab versus 16.7% with ezetimibe (P<0.001) [9]. Alirocumab monotherapy data in statin-intolerant patients from the ODYSSEY ALTERNATIVE trial (N=361) showed 45% LDL-C reduction at 24 weeks [10].

Titration Protocol in Practice: A Step-by-Step Comparison

The table below summarizes the standard titration approach for each agent in a high-intensity statin background patient with LDL-C starting at 110 mg/dL and a goal of <70 mg/dL.

| Step | Alirocumab | Evolocumab | |------|-----------|-----------| | Week 0 | 75 mg Q2W injection | 140 mg Q2W injection | | Week 4 | Check LDL-C | Check LDL-C (optional) | | Week 8 | Titrate to 150 mg Q2W if LDL-C >50 mg/dL | No change required | | Week 12 | Confirm target achieved | Confirm target achieved | | Monthly option | 300 mg Q4W if stable | 420 mg Q4W |

For the patient above, a 47% reduction from alirocumab 75 mg would bring LDL-C to approximately 58 mg/dL, clearing the <70 mg/dL target without escalation. Evolocumab's fixed dose would deliver approximately 65 mg/dL (59% reduction), also clearing target but offering no intermediate stopping point. When the goal is achieved comfortably at the lower alirocumab dose, the patient avoids the higher cost and slightly higher injection volume of 150 mg.

Monitoring Schedule for Alirocumab Titration

The ACC/AHA Guideline on the Management of Blood Cholesterol (2018) recommends a fasting lipid panel four to twelve weeks after PCSK9 inhibitor initiation and every three to twelve months thereafter [8]. With alirocumab specifically, an eight-week lipid check is operationally needed to make the titration decision. Clinicians should build this visit (or a telehealth lab check-in) into the prescribing workflow from day one to avoid the dose remaining at 75 mg longer than necessary if escalation is indicated.

Monitoring Schedule for Evolocumab

Because evolocumab has no titration decision point, the first follow-up lipid panel primarily confirms adherence and expected response rather than driving a prescribing change. Some clinicians check at four weeks to confirm the patient is injecting correctly and document baseline response, but the ACC/AHA guideline does not require a check before the standard three-to-twelve-month window [8].

Switching Between Repatha and Praluent

Switching from one PCSK9 inhibitor to the other does not require a washout period. The half-life of evolocumab is approximately 11 to 17 days; alirocumab's half-life is 17 to 20 days [2, 11]. Both are fully cleared within about five half-lives, but there is no rebound hypercholesterolemia during a switch. The most common clinical reason to switch is insurance formulary preference, prior authorization requirements, or patient preference for titration flexibility versus fixed dosing.

Formulary and Cost Considerations

Both agents carry list prices above $500 per month in the United States, with net prices after manufacturer rebates substantially lower. Patient assistance programs from both Amgen (Repatha) and Sanofi/Regeneron (Praluent) offer co-pay cards that reduce out-of-pocket costs significantly for commercially insured patients. For Medicare Part D patients, the Inflation Reduction Act caps out-of-pocket drug costs starting in 2025, which may reduce the cost differential between the two agents.

Step-by-Step Switching Protocol

When switching from evolocumab to alirocumab, administer the first alirocumab 75 mg injection at the time the next evolocumab dose would have been due. If the patient was previously achieving adequate LDL-C control on evolocumab, starting at 75 mg alirocumab is appropriate, with an eight-week lipid check to confirm adequacy. If the patient had previously required 420 mg monthly evolocumab and had LDL-C near but not below target, starting alirocumab at 150 mg every two weeks is reasonable to avoid a gap in efficacy.

When switching from alirocumab to evolocumab, administer the first 140 mg evolocumab injection at the time the next alirocumab dose would have been due. No dose adjustment or special monitoring beyond the standard three-to-twelve-month lipid check is required [8].

Should I Switch from Repatha to Praluent?

Switching is reasonable if alirocumab's titration flexibility serves a clinical purpose in your specific case, if your insurance formulary favors Praluent with lower cost-sharing, or if your LDL-C target can be met on the lower 75 mg alirocumab starting dose. Switching is not clinically necessary if LDL-C is at goal and the current agent is well tolerated. A 2023 real-world claims analysis found no significant difference in 12-month major adverse cardiovascular event rates between patients initiated on evolocumab versus alirocumab after adjusting for baseline risk (adjusted HR 0.97, 95% CI 0.89-1.06) [12].

The ACC/AHA guideline does not recommend one agent over the other based on cardiovascular outcome superiority, stating that "both evolocumab and alirocumab are acceptable options in patients with ASCVD not at goal on maximally tolerated statin therapy" [8].